We use cookies on your browser to customize content for your viewing and for analytics. If you click “Accept” or continue to browse our website, we assume you have agreed to our use of cookies. For details, please refer to our Cookies Policy.
11 December
189
Pulnovo Medical Limited, a globally recognized pioneer in medical device for Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the successful market use of its PADN products in two patients in Hong Kong. This marks a significant milestone in the global commercialization journey of Pulnovo Medical's innovative PADN system, further solidifying its role in advancing the treatment of pulmonary vascular diseases.
Under the guidance of Professor Shaoliang Chen from Nanjing Medical University and Professor Xiang Chen from Xiamen Cardiovascular Hospital, leading cardiology teams in Hong Kong collaborated to perform the procedures on two patients suffering from severe pulmonary hypertension.
At Queen Elizabeth Hospital, the procedure was led by Dr. Lee Michael Kang Yin, Dr. Esmond Yan Hang Fong, and their team. Renowned for their expertise in interventional therapy and clinical excellence, the team utilized the PADN system seamlessly, achieving significant improvements in patients’ hemodynamic parameters post-operation.
Similarly, a procedure at Queen Mary Hospital, in collaboration with Grantham Hospital, was led by Dr. Wong Ka Lam, Dr. Lam Lap Tin, and their team. Their extensive experience with pulmonary hypertension allowed them to leverage the PADN system’s simplicity and precision effectively, leading to notable symptom relief and hemodynamic improvements in the patients.
About PADN
Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery intervention procedure that uses a PADN catheter to deliver radiofrequency energy to the sympathetic nerves in the outer membrane of the pulmonary artery, resulting in the disappearance of the myelin sheath of the nerves and the fusion of the axons, which inhibits sympathetic activity, increases cardiac output, reduces pulmonary artery pressure , inhibits the pathologic remodeling of the pulmonary arteries, improves the patient's exercise endurance and cardiac function, and achieves long-term benefits from a single minimally invasive procedure.
About Pulnovo Medical
Founded in 2013, Pulnovo Medical Limited is a globally recognized leader in devices for the treatment of pulmonary hypertension and heart failure. Driven by innovation, Pulnovo is committed to advancing breakthrough technologies that offer therapeutic benefits to patients around the world.